Neuroleptic Malignant Syndrome Associated with Lithium Toxicity

Overview

Journal Oman Med J

Specialty General Medicine

Date 2016 Jul 13

PMID 27403245

Citations 10

Authors

Vaibhav Patil

Rishab Gupta

Rohit Verma

Yatan Pal Singh Balhara

Affiliations

Soon will be listed here.

Abstract

Neuroleptic Malignant Syndrome (NMS) is an idiosyncratic and potentially life-threatening reaction to neuroleptic drugs. Lithium is a first-line mood stabilizer used in the treatment and prophylaxis of bipolar disorder. There are several case reports of lithium-associated NMS, but only when it was given in combination with antipsychotics. Therefore, the possibility of NMS being secondary to the antipsychotics could not be ruled out in those cases. Here we present a case of lithium-induced NMS in a patient who was not being treated concomitantly with any other agent known to cause NMS. The patient, a 74-year-old female with a 30-year history of bipolar affective disorder, was admitted to the emergency room of the All India Institute of Medical Sciences, New Delhi, with history of high fever and generalized weakness for 10 days before the admission. NMS was established based the presence of three cardinal symptoms. She was started on intravenous fluids to correct her sodium levels slowly and requested to follow-up at the psychiatry clinic.

Citing Articles

A real-world pharmacovigilance study of neuroleptic malignant syndrome based on FDA adverse event reporting system.

Zhang Y, Deng W, Wang M, Luo S, Li S Front Pharmacol. 2024; 15:1438661.

PMID: 39723245 PMC: 11668602. DOI: 10.3389/fphar.2024.1438661.

Acute kidney injury induced lithium toxicity with concomitant neuroleptic malignant syndrome.

Lai Y, Mokhtar N, Samsudin I, Thambiah S Biomedicine (Taipei). 2024; 14(3):49-52.

PMID: 39386183 PMC: 11460575. DOI: 10.37796/2211-8039.1459.

Long prodromal symptoms of neuroleptic malignant syndrome in patient with intellectual developmental disorder-A case report.

Sadati S, Elyasi F, Shyasi Z, Rouhanizadeh B Neuropsychopharmacol Rep. 2024; 44(3):521-525.

PMID: 38832410 PMC: 11544438. DOI: 10.1002/npr2.12454.

Challenges in the Clinical Diagnosis of Lithium Toxicity: A Case Report.

Almadani A, AlBuqami F, Aljaffer M Cureus. 2023; 15(10):e47503.

PMID: 38021641 PMC: 10663876. DOI: 10.7759/cureus.47503.

Neuroleptic Malignant Syndrome with Low Dose Lithium, Without Concomitant Antipsychotics.

Ramadas S, Nitin Murali T N , Krishnan J, Andrade C Indian J Psychol Med. 2023; 45(1):92-94.

PMID: 36778604 PMC: 9896103. DOI: 10.1177/02537176221099307.

References

Stubner S, Rustenbeck E, Grohmann R, Wagner G, Engel R, Neundorfer G . Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry. 2004; 37 Suppl 1:S54-64. DOI: 10.1055/s-2004-815511. View

Levenson J . Neuroleptic malignant syndrome. Am J Psychiatry. 1985; 142(10):1137-45. DOI: 10.1176/ajp.142.10.1137. View

Supariwala A, Kant G, Jean R . Neuroleptic malignant syndrome with metoclopramide overdose coexisting with Clostridium difficile diarrhea. Intensive Care Med. 2011; 37(10):1706-8. DOI: 10.1007/s00134-011-2250-0. View

Gurrera R, Caroff S, Cohen A, Carroll B, DeRoos F, Francis A . An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011; 72(9):1222-8. DOI: 10.4088/JCP.10m06438. View

Borovicka M, Bond L, Gaughan K . Ziprasidone- and lithium-induced neuroleptic malignant syndrome. Ann Pharmacother. 2005; 40(1):139-42. DOI: 10.1345/aph.1G470. View

Ali S, Pearlman R, Upadhyay A, Patel P . Neuroleptic malignant syndrome with aripiprazole and lithium: a case report. J Clin Psychopharmacol. 2006; 26(4):434-6. DOI: 10.1097/01.jcp.0000227698.49246.6b. View

Gill J, Singh H, Nugent K . Acute lithium intoxication and neuroleptic malignant syndrome. Pharmacotherapy. 2003; 23(6):811-5. DOI: 10.1592/phco.23.6.811.32179. View

Trollor J, Chen X, Sachdev P . Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs. 2009; 23(6):477-92. DOI: 10.2165/00023210-200923060-00003. View

Erol A, Putgul G, Sert E, Mete L . [Clozapine-associated neuroleptic malignant syndrome followed by catatonia: a case report]. Turk Psikiyatri Derg. 2013; 24(2):140-4. View

10.

Gortney J, Fagan A, Kissack J . Neuroleptic malignant syndrome secondary to quetiapine. Ann Pharmacother. 2009; 43(4):785-91. DOI: 10.1345/aph.1L371. View

11.

Sharma B, Sannegowda R, Gandhi P, Dubey P, Panagariya A . Combination of Steven-Johnson syndrome and neuroleptic malignant syndrome following carbamazepine therapy: a rare occurrence. BMJ Case Rep. 2013; 2013. PMC: 3702838. DOI: 10.1136/bcr-2013-008908. View

12.

Tripathi P, Agrawal H, Goyal P, Kar S . Olanzapine-induced neuroleptic malignant syndrome in a patient with bipolar affective disorder: Does quetiapine holds the solution?. Ind Psychiatry J. 2014; 22(2):159-60. PMC: 4085812. DOI: 10.4103/0972-6748.132934. View

13.

Birmes P, Coppin D, Schmitt L, Lauque D . Serotonin syndrome: a brief review. CMAJ. 2003; 168(11):1439-42. PMC: 155963. View

14.

Argyriou A, Drakoulogona O, Karanasios P, Kouliasa L, Leonidou L, Giannakopoulou F . Lithium-induced fatal neuroleptic malignant syndrome in a patient not being concomitantly treated with commonly offending agents. J Pain Symptom Manage. 2012; 44(6):e4-6. DOI: 10.1016/j.jpainsymman.2012.08.010. View

15.

Manji H, Potter W, Lenox R . Signal transduction pathways. Molecular targets for lithium's actions. Arch Gen Psychiatry. 1995; 52(7):531-43. DOI: 10.1001/archpsyc.1995.03950190013003. View

16.

Hirschowitz J, Kolevzon A, Garakani A . The pharmacological treatment of bipolar disorder: the question of modern advances. Harv Rev Psychiatry. 2010; 18(5):266-78. DOI: 10.3109/10673229.2010.507042. View

17.

Verma R, Junewar V, Rathaur B . An atypical case of neuroleptic malignant syndrome precipitated by valproate. BMJ Case Rep. 2014; 2014. PMC: 3948000. DOI: 10.1136/bcr-2013-202578. View

18.

Arslankoylu A, Kutuk M, Okuyaz C, Toros F . Neuroleptic malignant syndrome due to risperidone misdiagnosed as status epilepticus. Pediatr Rep. 2011; 3(3):e19. PMC: 3207307. DOI: 10.4081/pr.2011.e19. View

19.

Ladds B, Thomas P, Mejia C, Hauser D . Extreme elevation of creatinine phosphokinase levels in neuroleptic malignant syndrome associated with atypical antipsychotics. Am J Psychiatry. 2009; 166(1):114-5. DOI: 10.1176/appi.ajp.2008.08101485. View